Cargando…

One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease

Fabry nephropathy is associated with progressive accumulation of globotriaosylceramide (GL3) in podocytes. Reducing this GL3 burden may reduce podocyte injury. Sensitive methods to quantify podocyte GL3 content may determine whether a given strategy can benefit podocytes in Fabry disease. We develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Najafian, Behzad, Tøndel, Camilla, Svarstad, Einar, Sokolovkiy, Alexey, Smith, Kelly, Mauer, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833322/ https://www.ncbi.nlm.nih.gov/pubmed/27081853 http://dx.doi.org/10.1371/journal.pone.0152812

Ejemplares similares

Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease
por: Mauer, Michael, et al.
Publicado: (2014)

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
por: Mauer, Michael, et al.
Publicado: (2017)

Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy
por: Fall, Brent, et al.
Publicado: (2016)

Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy
por: Braun, Fabian, et al.
Publicado: (2023)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease
por: Ishii, Satoshi, et al.
Publicado: (2020)

Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
por: Tsukimura, Takahiro, et al.
Publicado: (2021)

Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease
por: Taguchi, Atsumi, et al.
Publicado: (2023)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion
por: Kamani, Mustafa A, et al.
Publicado: (2016)

Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy
por: Gaggl, Martina, et al.
Publicado: (2016)

Gene Expression Analysis in gla-Mutant Zebrafish Reveals Enhanced Ca(2+) Signaling Similar to Fabry Disease
por: Elsaid, Hassan Osman Alhassan, et al.
Publicado: (2022)

Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla(−/−) zebrafish model of Fabry disease
por: Elsaid, Hassan Osman Alhassan, et al.
Publicado: (2023)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial
por: Wijburg, Frits A., et al.
Publicado: (2015)

Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy
por: Hongo, Kenichi, et al.
Publicado: (2020)

Serum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea
por: Kim, Jeong-Yup, et al.
Publicado: (2010)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy
por: Liguori, Rocco, et al.
Publicado: (2017)

Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype
por: Elsaid, Hassan O.A., et al.
Publicado: (2022)

A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse
por: Shin, Seok-Ho, et al.
Publicado: (2018)

Divergent Impact of Enzyme Replacement Therapy on Human Cardiomyocytes and Enterocytes Affected by Fabry Disease: Correlation with Mannose-6-phosphate Receptor Expression
por: Frustaci, Andrea, et al.
Publicado: (2022)

Role of Globotriaosylceramide in Physiology and Pathology
por: Celi, Ana Beatriz, et al.
Publicado: (2022)

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
por: Birklé, Stéphane, et al.
Publicado: (2013)

Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types
por: Welford, R W D, et al.
Publicado: (2018)

Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
por: Shiga, Tomoko, et al.
Publicado: (2021)

Accuracy of single intravenous access iohexol GFR in children is hampered by marker contamination
por: Eide, Thea Tislevoll, et al.
Publicado: (2021)

Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease
por: Nguyen Dinh Cat, Aurelie, et al.
Publicado: (2012)

Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times
por: Tøndel, Camilla, et al.
Publicado: (2016)

MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease
por: Maier, Nadine, et al.
Publicado: (2021)

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

Ceria-Zirconia nanoparticles reduce intracellular globotriaosylceramide accumulation and attenuate kidney injury by enhancing the autophagy flux in cellular and animal models of Fabry disease
por: An, Jong Hun, et al.
Publicado: (2022)

Predilection of Segmental Glomerulosclerosis Lesions for the Glomerulotubular Junction Area in Type 1 Diabetic Patients: A Novel Mapping Method
por: Najafian, Behzad, et al.
Publicado: (2013)

Dysregulated Autophagy Contributes to Podocyte Damage in Fabry’s Disease
por: Liebau, Max C., et al.
Publicado: (2013)

Elevated Ambulatory Blood Pressure Measurements are Associated with a Progressive Form of Fabry Disease
por: Rossi, Federica, et al.
Publicado: (2021)

Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy
por: Nordin, Sabrina, et al.
Publicado: (2019)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
por: Moore, David F, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_nm85t5ksjmebpah8j9gpn2fble